Nkarta, Inc. (NKTX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
2.79 USD
-0.18
(-6.061%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:44 a.m. EDT
The investment case here is structurally broken. Despite a recent regulatory win and a massive 214% price rebound last year, the company is trapped in a death spiral of deteriorating fundamentals. The five-year trajectory shows a catastrophic -96% cumulative loss, driven by four consecutive years of negative annual performance, indicating that the market has thoroughly priced out the business model. The balance sheet is fragile with negative free cash flow and negative equity returns, and the leadership is actively selling shares, which undermines any confidence in management's ability to navigate the crisis. While the short-term chart shows some bounce off lows, the lack of institutional support and the overwhelming options positioning for downside suggest this is a 'value trap' where the price has already fallen far too much to offer a margin of safety. There is no dividend to provide income, and the path to profitability remains obscured. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.136713 |
| MSTL | 0.153465 |
| AutoARIMA | 0.161775 |
| AutoTheta | 0.224891 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 1.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.862 |
| Excess Kurtosis | -0.37 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 26.237 |
| Market Cap | 199,611,552 |
| Forward P/E | -1.69 |
| Beta | 0.92 |
| Website | https://www.nkartatx.com |
As of July 11, 2026, 5:44 a.m. EDT: Speculators are heavily positioned for downside protection with deep out-of-the-money put volume dominating the open interest profile across multiple expirations, while call activity remains sparse and concentrated near the money. This asymmetry suggests a market consensus expecting further weakness rather than a catalyst-driven rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.57142854 |
| Address1 | 1,150 Veterans Boulevard |
| All Time High | 79.16 |
| All Time Low | 1.28 |
| Ask | 3.52 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 1,012,010 |
| Average Daily Volume3 Month | 838,462 |
| Average Volume | 838,462 |
| Average Volume10Days | 1,012,010 |
| Beta | 0.915 |
| Bid | 2.17 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 4.01 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.79 |
| Current Ratio | 12.956 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.025 |
| Day Low | 2.735 |
| Debt To Equity | 26.237 |
| Display Name | Nkarta |
| Earnings Timestamp | 1,778,616,000 |
| Earnings Timestamp End | 1,786,564,800 |
| Earnings Timestamp Start | 1,786,564,800 |
| Ebitda | -106,034,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.417 |
| Enterprise Value | 44,183,548 |
| Eps Current Year | -1.48 |
| Eps Forward | -1.65 |
| Eps Trailing Twelve Months | -1.35 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9316 |
| Fifty Day Average Change | -0.14160013 |
| Fifty Day Average Change Percent | -0.048301313 |
| Fifty Two Week Change Percent | 57.142853 |
| Fifty Two Week High | 3.72 |
| Fifty Two Week High Change | -0.93000007 |
| Fifty Two Week High Change Percent | -0.25000003 |
| Fifty Two Week Low | 1.7 |
| Fifty Two Week Low Change | 1.0899999 |
| Fifty Two Week Low Change Percent | 0.6411764 |
| Fifty Two Week Range | 1.7 - 3.72 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,594,387,800,000 |
| Float Shares | 60,442,949 |
| Forward Eps | -1.65 |
| Forward P E | -1.6909091 |
| Free Cashflow | -57,381,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 108 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04881 |
| Held Percent Institutions | 0.80747 |
| Implied Shares Outstanding | 71,545,358 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-10 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. |
| Long Name | Nkarta, Inc. |
| Market | us_market |
| Market Cap | 199,611,552 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_544531597 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -99,933,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 199,611,548 |
| Number Of Analyst Opinions | 6 |
| Open | 2.925 |
| Operating Cashflow | -87,286,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 925 407 1049 |
| Pre Market Change | -0.07999992 |
| Pre Market Change Percent | -2.8673809 |
| Pre Market Price | 2.71 |
| Pre Market Time | 1,784,016,021 |
| Previous Close | 2.97 |
| Price Eps Current Year | -1.885135 |
| Price Hint | 4 |
| Price To Book | 0.69576055 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.749 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.18 |
| Regular Market Change Percent | -6.06061 |
| Regular Market Day High | 3.025 |
| Regular Market Day Low | 2.735 |
| Regular Market Day Range | 2.735 - 3.025 |
| Regular Market Open | 2.925 |
| Regular Market Previous Close | 2.97 |
| Regular Market Price | 2.79 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 629,667 |
| Return On Assets | -0.17097999 |
| Return On Equity | -0.3007 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 71,545,358 |
| Shares Percent Shares Out | 0.0473 |
| Shares Short | 3,380,838 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,227,290 |
| Short Name | Nkarta, Inc. |
| Short Percent Of Float | 0.0591 |
| Short Ratio | 5.57 |
| Source Interval | 15 |
| State | CA |
| Symbol | NKTX |
| Target High Price | 16.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 11.33333 |
| Target Median Price | 11.0 |
| Total Cash | 230,428,000 |
| Total Cash Per Share | 3.221 |
| Total Debt | 75,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.36925 |
| Two Hundred Day Average Change | 0.4207499 |
| Two Hundred Day Average Change Percent | 0.17758779 |
| Type Disp | Equity |
| Volume | 629,667 |
| Website | https://www.nkartatx.com |
| Zip | 94,080 |